培美曲塞联合顺铂与多西他赛联合顺铂治疗非小细胞肺癌的临床效果对比  

Comparison of clinical effects of pemetrexed combined with cisplatin and docetaxel with cisplatin in treatment of non-small cell lung cance

作　　者：郭宏燕 崔抗[2] 杨红梅 王圆[2] GUO Hong-yan;CUI Kang;YANG Hong-mei;WANG Yuan(Out-patient Department,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院门诊部,郑州450052 [2]郑州大学第一附属医院肿瘤科,郑州450052

出　　处：《医药论坛杂志》2024年第4期424-427,432,共5页Journal of Medical Forum

摘　　要：目的对比观察培美曲塞联合顺铂和多西他赛联合顺铂治疗非小细胞肺癌的效果及患者治疗前后的各肿瘤标志物的变化。方法选取郑州大学第一附属医院收治的非小细胞肺癌患者110例纳入研究,根据使用药物不同分组,将通过多西他赛+顺铂的方案进行治疗的55例患者作为对照组,通过培美曲塞+顺铂的方案进行治疗的55例作为观察组,主要比较两组患者不同治疗方案下的临床疗效。结果观察组缓解率96.36%,显著高于对照组的81.81%(P<0.05);观察组的中位生存时间(18.37±6.43)个月,长于对照组的(8.21±3.98)个月(P<0.05),但是无生存进展时间以及一年生存率分别是(5.38±0.52)个月和65.45%,与对照组比较差异无统计学意义(P>0.05);治疗前两组肿瘤标志物糖类抗原125(carbohydrate antigen 125,CAl25)、细胞角蛋白19片段(Cytokeratin-19-fragment,CYFRA21-1)水平比较无统计学意义(P>0.05),治疗后均降低,且观察组均低于对照组(P<0.05);观察组不良反应发生率1.81%,低于对照组的16.36%(P<0.05)。结论将培美曲塞+顺铂的方案应用于非小细胞肺癌患者的治疗中,效果优于多西他赛+顺铂,有较高的应用价值,值得推广。Objective To observe the effect of pemetrexed combined with cisplatin and docetaxel combined with cisplatin in the treatment of non-small cell lung cancer and the changes of tumor markers before and after treatment.Methods A total of 110 patients with non-small cell lung cancer admitted to the hospital from January to December 2022 were includ-ed in the study.According to different drug groups,55 patients treated with docetaxel+cisplatin were selected as the con-trol group,and 55 patients treated with pemetrexed+cisplatin were selected as the observation group.The clinical efficacy of two groups of patients under different treatment schemes was compared.Results The remission rate of observation group was 96.36%,which was significantly higher than that of control group(81.81%)(P<0.05).The median survival time of the observation group was(18.37±6.43)months,which was longer than that of the control group(8.21±3.98)months(P<0.05),but the time without survival progression and one-year survival rate were(5.38±0.52)months and 65.45%,respectively,with no statistical significance compared with the control group(P>0.05).There was no signifi-cant difference in carbohydrate antigen 125(CAl25)and Cytokeratin-19-fragment(CYFRA21-1)levels between the two groups before treatment(P>0.05).After treatment,all of them were lower than that of control group(P<0.05).The incidence of adverse reactions in observation group was 1.81%,which was lower than that in control group(16.36%)(P<0.05).Conclusion Pemetrexed plus cisplatin is better than docetaxel plus cisplatin in the treatment of patients with non-small cell lung cancer,which has high application value and is worth promoting.

关 键 词：非小细胞肺癌 培美曲塞 多西他赛 顺铂 以及血清癌胚抗原(carcinoembryonic antigen CEA) 

分 类 号：R734.2[医药卫生—肿瘤]